Episode 8. Management of Newly Diagnosed CLL
Blood Cancer Talks
00:00
The Future of PI3 Kinase Inhibitors for CLL
There are two PI3 kinase inhibitor approved for CLL, namely Dileysive and Dibleysive. There was a third one called Pumbrolysive, which actually I was really hopeful for. But early part of the CLL was withdrawn by the company because of some toxicities or whatnot. So you have to really think of third generation BTK inhibitor, like Brute-Neb or some kind of a clinical trial with thirdgeneration BTK inhibitors.
Transcript
Play full episode
